Evidence map›Paper›PMID 32817081›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Methylomic Landscapes of Ovarian Cancer Precursor Lesions.

Thomas R Pisanic, Yeh Wang, Hanru Sun, Michael Considine, Lihong Li, Tza-Huei Wang, Tian-Li Wang, Ie-Ming Shih

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06140992 (PaCIFiC-CUP:Pan-Cancer Integrated Fingerprinting Classifier for Identifying the Origin of Cancer of Unknown Primary), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06140992 recruitingnot on this mapstarted 2023, after this paper: background citation

PaCIFiC-CUP:Pan-Cancer Integrated Fingerprinting Classifier for Identifying the Origin of Cancer of Unknown Primary: A Multi-Center Prospective Cohort Study

TypeobservationalSponsorSun Yat-sen UniversityRan2023 to 2026Enrolled120ConditionsUnknown Primary Tumors, DNA Methylation
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.Diagnostics (Basel, Switzerland) · 2022
    Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Thomas R Pisanic *Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland. tpisanic@jhu.edu ishih@jhmi.edu.
Yeh Wang *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Hanru SunJohns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland.
Michael ConsidineDepartment of Biostatistics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lihong LiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Tza-Huei WangJohns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland.
Tian-Li WangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ie-Ming ShihDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. tpisanic@jhu.edu ishih@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Tian-Li Wang · 2018 to 2026
$20.5M
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancerU01CA200469 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHIH, IE-MING, ZHANG, ZHEN · 2016 to 2021
$2.9M
Experimental Therapeutics by targeting Spleen Tyrosine KinaseR01CA215483 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHIH, IE-MING · 2017 to 2021
$1.9M
NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA215483NCI NIH HHS U01 CA200469
6 · The paper itself

Abstract

purposeThe current paradigm in the development of high-grade serous ovarian carcinoma (HGSC) proposes that the majority of HGSCs arise from precursor serous tubal intraepithelial carcinoma (STIC) lesions of the fallopian tube. Here we survey genome-wide methylation in HGSC precursor lesions to identify genomic regions that exhibit high-specificity differential hypermethylation for potential use as biomarkers for detecting STIC and HGSC at stages when curative intervention likely remains feasible. EXPERIMENTAL

designWe first identified quality control criteria for performing reliable methylomic analysis of DNA-limited tubal precursor lesions with the Illumina Infinium MethylationEPIC array. We then used this platform to compare genome-wide methylation among 12 STICs with paired adjacent-normal epithelia, one p53 signature lesion and two samples of concurrent HGSC. The resulting methylomic data were analyzed by unsupervised hierarchical clustering and multidimensional analysis. Regions of high-confidence STIC-specific differential hypermethylation were identified using selective bioinformatic criteria and compared with published MethylationEPIC data from 23 HGSC tumors and 11 healthy fallopian tube mucosae.

resultsUnsupervised analysis showed that STICs largely clustered with HGSCs, but were clearly distinct from adjacent-normal fallopian tube epithelia. Forty-two genomic regions exhibited high-confidence STIC-specific differential hypermethylation, of which 17 (40.5%) directly overlapped with HGSC-specific differentially methylated regions. Methylation at these shared loci was able to completely distinguish STIC and HGSC samples from normal and adjacent-normal specimens.

conclusionsOur results suggest that most STICs are epigenetically similar to HGSCs and share regions of differential hypermethylation that warrant further evaluation for potential use as biomarkers for early detection of ovarian HGSC.

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticAdultAgedBiomarkers, TumorCase-Control StudiesCystadenocarcinoma, SerousFallopian Tube NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedOvarian NeoplasmsPrecancerous ConditionsPrognosisRetrospective StudiesBiomarkers, Tumor

Identifiers

PMID32817081
PMCPMC7710556
OpenAlexW3077254858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.